VistaGen Therapeutics (NASDAQ:VTGN) Stock Crosses Below Fifty Day Moving Average – Should You Sell?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.64 and traded as low as $0.5503. VistaGen Therapeutics shares last traded at $0.5574, with a volume of 315,608 shares changing hands.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Wall Street Zen raised shares of VistaGen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Stifel Nicolaus cut shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $0.90 price target (down from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, VistaGen Therapeutics has an average rating of “Reduce” and a consensus target price of $0.95.

VistaGen Therapeutics Stock Up 1.2%

The stock’s 50-day moving average price is $0.64 and its 200-day moving average price is $2.69. The company has a market capitalization of $22.08 million, a price-to-earnings ratio of -0.29 and a beta of 0.32.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.06. The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.14 million. On average, equities research analysts anticipate that VistaGen Therapeutics, Inc. will post -1.77 EPS for the current year.

Hedge Funds Weigh In On VistaGen Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in VistaGen Therapeutics in the fourth quarter worth about $25,000. Tudor Investment Corp ET AL acquired a new position in VistaGen Therapeutics during the 4th quarter valued at about $50,000. Millennium Management LLC boosted its stake in shares of VistaGen Therapeutics by 853.0% in the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock valued at $130,000 after purchasing an additional 176,369 shares during the last quarter. Luminus Management LLC acquired a new stake in shares of VistaGen Therapeutics during the 4th quarter worth approximately $232,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of VistaGen Therapeutics during the 4th quarter worth approximately $68,000. Institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.